ベータ
治験レーダーAI
治験 NCT04228978 (PROVE)(対象:末梢動脈疾患、過体重または肥満)は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss (PROVE)

募集中
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます!「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT04228978 (PROVE) は 介入研究 臨床試験 で、末梢動脈疾患、過体重または肥満 に関するものです。現在は 募集中 で、2020年3月1日 から開始しています。212 名の参加者 の募集が計画されています。この治験は ノースウェスタン大学 によって主催され、2027年5月31日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2024年9月26日 です。
概要
The PROVE Trial is a randomized clinical trial that will determine whether a weight loss intervention combined with walking exercise achieves greater improvement or less decline in six-minute walk distance at 12 month follow-up than walking exercise alone in people with PAD and BMI>25 kg/m2. The intervention uses a Group Mediated Cognitive Behavioral framework, connective mobile technology, remote monitoring by a coach, and a calorie restricted Dietary Approaches to Stop Hypertension (DASH)-derived Optimal Macronutrient Intake Trial for Heart Health (OMNIHeart) diet.

212 participants with PAD and BMI > 25 kg/m2 will be randomized to one of two groups: weight loss + exercise (WL+EX) vs. exercise alone (EX). Participants will be randomized at Northwestern, Tulane University, and University of Minnesota. Our primary outcome is change in six-minute walk distance at 12-month follow-up. Secondary outcomes are change in 6-minute walk distance at 6-month follow-up and change in exercise adherence, physical activity, patient-reported walking ability (measured by the Walking Impairment Questionnaire (WIQ) distance score), and mobility (measured by the Patient-Reported Outcomes Measurement Information System [PROMIS] mobility questionnaire) at 12-month follow-up. Tertiary outcomes are perceived exertional effort (measured by the Borg scale at the end of the 6-minute walk at 12-month follow-up), and diet quality. Exploratory outcomes consist of change in the short physical performance battery (SPPB), the WIQ stair climbing and walking speed scores, and calf muscle biopsy measures at 12-month follow-up. Study investigators will perform calf muscle biopsies in 50 participants to compare changes in mitochondrial biogenesis and activity, capillary density, and inflammation between WL+EX vs. EX.

公式タイトル

PROmote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to preVEnt Mobility Loss: The PROVE Trial

疾患/病気
末梢動脈疾患過体重または肥満
刊行物
この臨床試験について発表された科学記事と研究論文:
その他の研究識別子
NCT番号
開始日
2020-03-01
最終更新日
2024-09-26
終了予定日
2027-05-31
目標参加者数
212
試験の種類
介入研究
治験の相・段階
該当なし
状況
募集中
主目的
治療
割付方法
無作為化
介入モデル
並行割当
盲検化
単盲検
群(アーム)/介入
参加グループ/群介入/治療法
実験的Weight loss + exercise (WL+EX)
Weight loss + home based walking exercise (WL+EX)
体重減少
Walking exercise combined with weight loss
運動
Walking exercise
実薬対照薬Exercise alone (EX)
Home based walking exercise (EX)
運動
Walking exercise
主要評価項目
評価指標指標の説明時間枠
12-month change in six-minute walk distance
Change in six-minute walk distance at 12-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.
Baseline to 12 months
副次評価項目
評価指標指標の説明時間枠
12-month change in minutes of walking exercise/week
Change in minutes walked for exercise in a week will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone at 12-month follow-up.
Baseline to 12 months
12-month change in physical activity measured by accelerometer data
Change in physical activity at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. Change in physical activity will be compared using accelerometer data.
Baseline to 12 months
12-month change in Walking Impairment Questionnaire (WIQ) distance score
Change in Walking Impairment Questionnaire (WIQ) distance score at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. The WIQ distance score ranges from 0-100 with a higher score indicating a better outcome.
Baseline to 12 months
12-month change in Patient-Reported Outcomes Measurement Information System (PROMIS) mobility questionnaire
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) mobility questionnaire score at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. A higher score is better. There is no set minimum and maximum values for the PROMIS questionnaire. However, a higher PROMIS score indicates a better outcome.
Baseline to 12 months
6-month change in 6-minute walk distance
Change in six-minute walk distance at 6-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.
Baseline to 6 months
適格基準

対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て

  1. Above or below knee amputation, critical limb ischemia, or wheelchair confinement.

  2. Walking is limited by a condition other than PAD.

  3. Failure to complete the study run-in, defined as not entering at least 800 Kcal of consumed calories per day for at least five days during the 14-day run-in*.

  4. Major surgery, coronary or leg revascularization in the past 3 months or anticipated in the next year.

  5. Experienced a heart attack or stroke in the past 3 months.

  6. Major medical illness including lung disease requiring oxygen or life-threatening illness, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent.

  7. Mini-Mental Status Examination (MMSE) score < 23, dementia and substance abuse. Potential participants with an MMSE score of less than 23 may be eligible if the principal investigator determines that their lower score is due to reasons other than poor cognition. Other potential reasons for lower scores include poor literacy or that English is not their first language.

  8. History of being treated for new onset or an acute episode of schizophrenia or psychosis in the past 6 months.

  9. Hospitalization for a psychiatric disorder in the past 6 months.

  10. BMI > 45 kg/m2

  11. History of a significant eating disorder that has been active within the past 5 years or any weight loss treatment in the past 6 months. Weight loss treatment includes weight watchers, any history of weight loss surgery, and using weight loss medications now or in the past six months.

  12. Weight gain or loss of more than 25 pounds in the past six months

  13. Potential participants unwilling/unable to use a smart phone and unwilling to attend weekly study sessions.

  14. Excessive alcohol use, defined as >14 drinks/week in men and > 10 alcoholic drinks/week in women.

  15. Current ulcer on bottom of foot

  16. Current participation in supervised treadmill exercise, participation in supervised treadmill exercise in the past three months, or planning to participate in supervised treadmill exercise in the next year

  17. Increase in angina or angina at rest. Potential participants may become eligible following an abnormal baseline treadmill stress test if they have evidence of an absence of coronary ischemia based on testing with their own physician.

  18. Non-English speaking

  19. Visual impairment that limits walking ability

  20. Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention

  21. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]

  22. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

    • The run-in will also be used to assist participants with learning the app. However, they must demonstrate ability to enter at least 800 Kcal per day for at least five days of the run-in.
Northwestern University logoノースウェスタン大学401 件のアクティブな治験を探索
責任者
Mary McDermott, 研究責任者, Jeremiah Stamler Professor, Northwestern University
試験中央連絡先
連絡先: Mary M McDermott, MD, 312-503-6419, [email protected]
連絡先: Kathryn J Domanchuk, BS, 312-503-6438, [email protected]
5 1カ国の場所

Illinois

Northwestern University, Chicago, Illinois, 60611, United States
Mary M McDermott, MD, 連絡先, 312-503-6419, [email protected]
Kathryn E Domanchuk, BS, 連絡先, 312-503-6438, [email protected]
募集中

Louisiana

Tulane University, New Orleans, Louisiana, 70130, United States
実施中/登録終了

Maryland

Johns Hopkins University, Baltimore, Maryland, 21287, United States
募集中

Michigan

Henry Ford Health, Detroit, Michigan, 48202, United States
Jonathan Ehrman, PhD, 連絡先, 313-972-4089, [email protected]
募集中

Minnesota

University of Minnesota, Minneapolis, Minnesota, 55455, United States
Diane Treat-Jacobson, PhD, 連絡先, 612-624-7613, [email protected]
募集中